Spots Global Cancer Trial Database for The Effects of NVX-108 as a Radiation Sensitizer in Glioblastoma
The following info and data is provided "as is" to help patients around the globe.
We do not endorse or review these studies in any way.
Trial Identification
Brief Title: The Effects of NVX-108 as a Radiation Sensitizer in Glioblastoma
Official Title: A Phase 1b Dose-finding, Pharmacokinetic and Pharmacodynamic Study of NVX-108 Combined With Radiation and Temozolomide in Patients With Newly-diagnosed Glioblastoma Multiforme
Study ID: NCT02189109
Conditions
Interventions
Study Description
Brief Summary: This clinical trial is testing the safety, tolerability and effectiveness of NVX-108 administered via intravenous infusion in combination with standard radiation and chemotherapy. NVX-108 is being developed to increase the amount of oxygen delivered to tumors which is hoped to increase the effectiveness of radiation therapy.
Detailed Description:
Eligibility
Minimum Age: 18 Years
Eligible Ages: ADULT, OLDER_ADULT
Sex: ALL
Healthy Volunteers: No
Locations
St. Vincents Hospital Sydney, Darlinghurst, New South Wales, Australia
Flinders Medical Centre, Adelaide, South Australia, Australia
Nucleus Network, Melbourne, Victoria, Australia
Epworth Center, Melbourne, Victoria, Australia
Contact Details
Name: Jason Lickliter, MBBSPhDFRACP
Affiliation: Nucleus Network
Role: PRINCIPAL_INVESTIGATOR
Take Control of Your Skin and Body Changes Today.
Try out Spots for free, set up only takes 2 mins.
Join others from around the world:
